









Markets
/
Stocks
/
nasdaq-crl
/

Charles River Laboratories International Inc

CRL

180.070USD

+0.960+0.54%

Close 10/31, 16:00（ET）Quotes delayed by 15 min

8.86BMarket Cap

LossP/E TTM



Charles River Laboratories International Inc

180.070

+0.960+0.54%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Charles River Laboratories International Inc

Currency: USD Updated: 2025-10-31

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Charles River Laboratories International Inc's Score

Industry at a Glance

Industry Ranking

51 / 407

Overall Ranking

131 / 4618

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 19 analysts

Hold

Current Rating

188.959

Target Price

+5.50%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Charles River Laboratories International Inc Highlights

StrengthsRisks

Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Undervalued

The company’s latest PE is -138.94, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 51.65M shares, decreasing 17.34% quarter-over-quarter.

Held by John Rogers

Star Investor John Rogers holds 1.42M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-31

The company's current financial score is 7.07, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 1.03B, representing a year-over-year increase of 0.59%, while its net profit experienced a year-over-year increase of 41.85%.

Score

Industry at a Glance

Previous score

7.07

Change



Financials

4.34

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.92

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.95

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.61

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

6.55

Key Metrics

Free cash flow

No Data

Charles River Laboratories International Inc's Company Valuation

Currency: USD Updated: 2025-10-31

The company’s current valuation score is 8.94, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -138.94, which is -782.85% below the recent high of 948.76 and -80.41% above the recent low of -250.66.

Score

Industry at a Glance

Previous score

8.94

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 51/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-31

The company’s current earnings forecast score is 6.95, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Charles River Laboratories International Inc is 195.00, with a high of 211.00 and a low of 157.42.

Score

Industry at a Glance

Previous score

6.95

Change

Support & Resistance

No Data

Analyst Rating

Based on 19 analysts

Hold

Current Rating

188.959

Target Price

+5.50%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Charles River Laboratories International Inc

CRL

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-31

The company’s current price momentum score is 6.83, which is higher than the Biotechnology & Medical Research industry's average of 6.66. Sideways: Currently, the stock price is trading between the resistance level at 197.53 and the support level at 164.73, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.78

Change

0.05

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.793

Neutral

RSI(14)

53.677

Neutral

STOCH(KDJ)(9,3,3)

25.495

Sell

ATR(14)

6.762

High Vlolatility

CCI(14)

-30.770

Neutral

Williams %R

59.726

Sell

TRIX(12,20)

0.663

Sell

StochRSI(14)

4.515

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

184.508

Sell

MA10

186.995

Sell

MA20

179.630

Buy

MA50

167.001

Buy

MA100

162.208

Buy

MA200

154.719

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-31

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.21. The latest institutional shareholding proportion is 104.95%, representing a quarter-over-quarter decrease of 7.99%. The largest institutional shareholder is The Vanguard, holding a total of 5.80M shares, representing 11.79% of shares outstanding, with 1.73% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

5.80M

-4.81%

Wellington Management Company, LLP

3.77M

-12.07%

BlackRock Institutional Trust Company, N.A.

2.75M

-5.39%

Allspring Global Investments, LLC

2.29M

+29.11%

State Street Investment Management (US)

1.86M

-2.30%

Nomura Securities Co., Ltd.

1.57M

+160.84%

Ariel Investments, LLC

Star Investors

1.42M

+28.58%

Geode Capital Management, L.L.C.

1.23M

-2.49%

Harris Associates L.P.

Star Investors

1.16M

Invesco Capital Management LLC

Star Investors

1.09M

+11.23%

Risk Assessment

Currency: USD Updated: 2025-10-31

The company’s current risk assessment score is 6.31, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.54. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.